The Innovation ETF Up 22% That Most Tech Investors Have Never Considered

Innovation-focused investors face a persistent dilemma: how to capture exposure to disruptive technologies without overpaying for hype or concentrating too heavily in mega-cap names. iShares Exponential Technologies ETF (NASDAQ:XT | XT Price Prediction) attempts to solve this by spreading capital across 500+ holdings targeting AI, genomics, robotics, and other exponential-growth sectors. After a decade in the market, the fund’s track record reveals whether this diversified innovation bet delivers on its promise.

The ETF’s Intended Portfolio Role

XT positions itself as a core technology and healthcare growth sleeve for investors who want broader innovation exposure than traditional tech indexes provide. The fund allocates 30.2% to information technology and 16% to healthcare, with meaningful positions in semiconductors, cybersecurity, biotech, and cloud infrastructure. Top holdings include Eli Lilly (NYSE:LLY) (2.82%), Tesla (NASDAQ:TSLA) (2.78%), and NVIDIA (NASDAQ:NVDA) (2.23%), but no single position exceeds 3%, creating a more balanced profile than concentrated tech funds.

The fund targets capital appreciation through businesses scaling AI chips, gene therapies, electric vehicles, and enterprise software. Its 43% annual turnover reflects active rebalancing to maintain exposure to emerging leaders. With $3.7 billion in assets and a 0.46% expense ratio, the fund offers institutional-quality access at a reasonable cost.

Does It Deliver?

Performance tells a mixed story. Over the past year, XT returned 22.63%, meaningfully outpacing both Invesco QQQ Trust (NASDAQ:QQQ) and SPDR S&P 500 ETF Trust (NYSEARCA:SPY) over the same period. The outperformance likely reflects XT’s broader sector exposure catching tailwinds outside the mega-cap names that dominate QQQ. Year-to-date in 2026, that momentum has continued, with XT up 3.91% while QQQ has slipped into negative territory.

The five-year record tells a different story. XT’s cumulative gain of roughly 31% badly trails QQQ’s 83% over the same period, a gap that reflects a specific market dynamic: the 2021–2026 cycle was dominated by a narrow group of mega-cap AI and cloud names that QQQ concentrates heavily. Because XT spreads capital across 500+ holdings to reduce single-stock risk, it structurally limits its ability to benefit when just five or ten companies drive the majority of index returns. That diversification is a feature in volatile or sector-rotating markets, but a drag during sustained mega-cap rallies.

The Tradeoffs

XT’s 0.76% dividend yield makes it unsuitable for income investors. The fund distributed a $5.33 per share payment in December 2025, but this appears to be a special capital gains distribution rather than sustainable income. Sector concentration creates cyclical risk, and international holdings add currency and geopolitical exposure that domestic-focused investors may not want. Active rebalancing also introduces tracking error, as performance depends partly on the manager’s sector timing decisions.

XT is a broadly diversified innovation fund that spreads exposure across 500+ holdings in technology, healthcare, and adjacent sectors, with no single position exceeding 3%. Its recent one-year performance has been strong relative to major benchmarks, while its five-year record reflects the structural tradeoffs of wide diversification during a period of concentrated mega-cap leadership.